Helmut Butzkueven
Helmut Butzkueven
MSNI Research Group, Dept of Neuroscience, Central Clinical School, Monash University
Verified email at monash.edu
Title
Cited by
Cited by
Year
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
S Sawcer, G Hellenthal, M Pirinen, CCA Spencer, NA Patsopoulos, ...
Nature 476 (7359), 214, 2011
23932011
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
AH Beecham, NA Patsopoulos, DK Xifara, MF Davis, A Kemppinen, ...
Nature genetics 45 (11), 1353, 2013
9612013
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity
R Roxburgh, SR Seaman, T Masterman, AE Hensiek, SJ Sawcer, ...
Neurology 64 (7), 1144-1151, 2005
8582005
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, R Simmons, ...
Bmj 327 (7410), 316, 2003
6642003
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability
CL Martin, BA Phillips, TJ Kilpatrick, H Butzkueven, N Tubridy, ...
Multiple Sclerosis Journal 12 (5), 620-628, 2006
5252006
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20
Australia and New Zealand Multiple Sclerosis Genetics Consortium
Nature genetics 41 (7), 824, 2009
4572009
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
4132018
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia
IAF van der Mei, AL Ponsonby, T Dwyer, L Blizzard, BV Taylor, T Kilpatrick, ...
Journal of neurology 254 (5), 581-590, 2007
3782007
Genome‐wide meta‐analysis identifies novel multiple sclerosis susceptibility loci
NA Patsopoulos, ...
Annals of neurology 70 (6), 897-912, 2011
3092011
LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival
H Butzkueven, JG Zhang, M Soilu-Hanninen, H Hochrein, F Chionh, ...
Nature medicine 8 (6), 613-619, 2002
2972002
Brain health: time matters in multiple sclerosis
G Giovannoni, H Butzkueven, S Dhib-Jalbut, J Hobart, G Kobelt, G Pepper, ...
Multiple sclerosis and related disorders 9, S5-S48, 2016
2182016
Onset seizures independently predict poor outcome after subarachnoid hemorrhage
H Butzkueven, AH Evans, A Pitman, C Leopold, DJ Jolley, AH Kaye, ...
Neurology 55 (9), 1315-1320, 2000
2162000
A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis
MS Stein, Y Liu, OM Gray, JE Baker, SC Kolbe, MR Ditchfield, GF Egan, ...
Neurology 77 (17), 1611-1618, 2011
2012011
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PLOS one 7 (10), e48078, 2012
1902012
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
1712016
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ...
The Lancet Neurology 16 (3), 189-199, 2017
1692017
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
1642019
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
H Butzkueven, L Kappos, F Pellegrini, M Trojano, H Wiendl, RN Patel, ...
Journal of Neurology, Neurosurgery & Psychiatry 85 (11), 1190-1197, 2014
1462014
Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians
JP Rubio, J Stankovich, J Field, N Tubridy, M Marriott, C Chapman, ...
Genes & Immunity 9 (7), 624-630, 2008
1452008
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of neurology 77 (3), 425-435, 2015
1442015
The system can't perform the operation now. Try again later.
Articles 1–20